COPD drug cuts asthma exacerbations

A commonly used COPD drug could be used to tackle poorly controlled asthma, research suggests.

Asthma: tiotropium cut relative risk of acute exacerbation
Asthma: tiotropium cut relative risk of acute exacerbation

Giving tiotropium to asthma patients who remained symptomatic despite treatment reduced the relative risk of acute exacerbation by 21%, according to a study published in the New England Journal of Medicine.

The phase III research, presented at the European Respiratory Society conference in Vienna, also showed adding the once-daily drug could cut the risk of any asthma exacerbation by 31%.

Tiotropium, a long-acting inhaled bronchodilator commonly used to treat COPD, is currently unlicensed for treating asthma.

In two trials supported by the drug's marketers, Boehringer Ingelheim and Pfizer, researchers recruited 912 patients with asthma already taking inhaled glucocorticoids and long-acting beta-agonists (LABAs).

Despite their drug regimen, all patients remained symptomatic and had at least one severe exacerbation within the past year.

Researchers randomised these patients to receive either tiotropium (5μg once daily) or placebo alongside their usual treatment. These were administed using a soft-mist inhaler.

The team found that after 24 weeks the average change in peak FEV1 from baseline was around 86ml greater among patients on tiotropium than placebo in the first trial, and 154ml greater in the second.

Patients receiving tiotropium went on average 282 days without a first exacerbation - 21% longer than those on placebo, who experienced an exacerbation within an average of 226 days. The effects were sustained over 24 hours.

Adverse events were similar between treatment and placebo groups.

The researchers concluded that 'in patients with poorly controlled asthma despite treatment with inhaled glucocorticoids and LABAs, adding tiotropium significantly reduced the risk of episodes of the worsening of asthma and asthma exacerbations requiring treatment with systemic glucocorticoids and provided sustained bronchodilation'.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...